It’s been a long and winding road for Agile Therapeutics and their quest in getting their birth-control patch, Twirla, FDA approved, but the final destination of FDA approval looks to be closer than ever before...
AVEO Oncology (NASDAQ: AVEO) announced they have hired a new CFO, Erick Lucera, as the company looks to work their way towards right the ship towards approval of their cancer drug, tivozanib...
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report a new peer review research report has been published on experimental studies of the Company's Fexapotide Triflutate treatment for prostate enlargement (BPH)...
As I’ve previously written, I started focusing on Biotech investing in late 2019, with Amarin, Agile Therapeutics and VBI Vaccines as my primary positions, with a couple of trades along the way, including Matinas and Neovasc...
Shares of Agile Therapeutics were higher by almost 20% in early trading after the company announced new additions to the company's management team in preparation for the potential commercialization of Twirla...
Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina...
If you're looking for the convenience, portability and style of wireless Bluetooth earbuds without sacrificing sound quality or durability, look no further than the $79 Kharbon IP67 Wireless Earbuds...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombinant human granulocyte...
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-07...
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the formation of a new subsidiary, Zilentin Ltd...